Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Heat on Roche to Cut Kadcyla Price After NICE 'No'

(Pharma Times [UK]) Apr 23, 2014 - Breast cancer care campaigners have slammed draft guidelines from the National Institute for Health and Care Excellence turning down NHS funding for Roche's Kadcyla (trastuzumab emtansine) because it costs "tens of thousands of pounds more than other treatments".

Commentary: So a rose by any other name is still a rose and rationing by any other name is still rationing. But this article...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Heat on Roche to Cut Kadcyla Price After NICE 'No'

(Pharma Times [UK]) Apr 23, 2014 - Breast cancer care campaigners have slammed draft guidelines from the National Institute for Health and Care Excellence turning down NHS funding for Roche's Kadcyla (trastuzumab emtansine) because it costs "tens of thousands of pounds more than other treatments".
read article »

NICE Recommends Bortezomib for Newly Diagnosed Blood Cancer, Multiple Myeloma

(NICE) Apr 22, 2014 - People newly diagnosed with the blood cancer multiple myeloma will now be guaranteed access to bortezomib, also known as Velcade.
read press release »

How Big Pharma Holds Back in the War on Cancer

(The Daily Beast) Apr 23, 2014 - Big Pharma’s focus on blockbuster cancer drugs squeezes out cheaper treatments. The result, one researcher says: ‘If we’re winning the war on cancer, we’re not winning that fast.’
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Heat on Roche to Cut Kadcyla Price After NICE 'No' (Pharma Times [UK])

So a rose by any other name is still a rose and rationing by any other name is still rationing. But this article...posted by: Thomas Marsland, MD

Response Genetics Enters Next Generation Sequencing Market With Proprietary Panel for Lung Cancer Developed by the Knight Cancer Institute at Oregon Health & Science University (Yahoo! Finance)

Although it is not specifically stated in the release, I assume that with the molecular profiling of the tumor...posted by: Winston Wong, PharmD

VA, California Panels Urge Costly Hepatitis C Drugs For Sickest Patients (Kaiser Health News)

Warehousing of Hep C patients is real. it took me a while to be convinced of that. The only question is whether...posted by: Winston Wong, PharmD

Drug Combo May Knock Down Lung Cancer (San Diego Union-Tribune)

The key comment made in the release is that the populations need tone very defined, implying, this is not for every...posted by: Winston Wong, PharmD

Robot Versus Surgeon: No Clear Winner (MedPage Today)

I recall the initial days when the robotic surgery technology first came to Hopkins. We, as the payer, were rather...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Novocure has posted 2 new jobs.


View OBR Job Board>>


KH_ASCO_Webinar_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
GALE +10.10%
EPZM +7.80%
SPPI +4.06%
PARD -34.34%
IMNP -11.80%
TGTX -11.34%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: Q2/Q3 2014
Company: Amgen
Product: Kyprolis® (carfilzomib)

Date: June 16, 2014
Company: Navidea Biopharmaceuticals
Product: Lymphoseek® (technetium Tc 99m tilmanocept) Injection

Date: mid-2014
Company: Incyte
Product: Jakafi® (ruxolitinib)

See All OBR Radar items»